Spyre Therapeutics
SYRE
137 hedge funds and large institutions have $1.08B invested in Spyre Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 43 reducing their positions, and 13 closing their positions.
91% more call options, than puts
Call options by funds: $1.6M | Put options by funds: $838K
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
13% more capital invested
Capital invested by funds: $953M → $1.08B (+$125M)
6% more funds holding
Funds holding: 129 → 137 (+8)
2% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 43
0.9% more ownership
Funds ownership: 105.56% → 106.45% (+0.9%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$17.9M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$13.3M |
| 3 |
Millennium Management
New York
|
+$6.66M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$6.09M |
| 5 |
JP Morgan Chase
New York
|
+$3.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.13M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$6.57M |
| 3 |
Morgan Stanley
New York
|
-$5.48M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5.43M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.05M |
SYRE Hedge Fund Activity: Q3 2025 in Review
137 of the 7,639 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2025, worth a combined $1.08B — up 13% from $953M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SYRE positions and 13 closed out — a net gain of 9 holders — while 44 added to existing stakes and 43 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $17.9M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $9.13M sold.
- 137 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2025, up from 129 in Q2 2025.
- Funds reported $1.08B of Spyre Therapeutics stock for Q3 2025, up 13% quarter-over-quarter.
- 22 funds opened new Spyre Therapeutics positions in Q3 2025 and 13 closed out, a net change of +9 holders.
- The largest Spyre Therapeutics buyer in Q3 2025 was TCG Crossover Management, an estimated $17.9M added.
- The largest Spyre Therapeutics seller in Q3 2025 was Adage Capital Partners, an estimated $9.13M sold.
Based on aggregated 13F filings for Q3 2025.